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Abstract 32 
Radical treatment of localised prostate cancer is recognised to be an unnecessary 33 
intervention or overtreatment in many men. Consequently, there has been a 34 
rapid uptake in the use of focal ablative therapies.  However, there are several 35 
biological and practical concerns about such approaches as they have yet to be 36 
proven as robust treatment options. In particular, the multi-focal nature of 37 
prostate cancer argues against unifocal treatment, while limitations in imaging 38 
can preclude the accurate identification of the number, location and extent of 39 
prostate cancer foci. To date, a number of ablative options have reported results 40 
on mainly low risk disease. Most series are relatively immature, with a lack of 41 
consistent follow up, and the morbidity of retreatment is often not considered. 42 
The authors consider focal therapy to be an investigational modality and 43 
 2 
encourage prospective recording of outcomes and the recruitment of suitable 44 
patients.  45 
 46 
I. Introduction 47 
Whole gland treatment is currently considered the optimum treatment for 48 
localised prostate cancer (PCa). However, since treatment of the entire prostate 49 
gland results in damage to surrounding tissue such as urinary sphincter, 50 
neurovascular bundle, bowel and bladder, a focused treatment for PCa lesions 51 
only, should they be accurately identified, would be of interest. Focal therapy 52 
(FT) of the prostate can be defined as treatment of specific areas of the prostate 53 
to minimise treatment-related morbidity and is facilitated by improvements in 54 
PCa imaging. The options for FT are numerous and focal ablation may reduce 55 
complications associated with whole gland treatment provided the same 56 
oncological efficacy is maintained (1, 2).  57 
Recent data from the ProtecT trial showed no difference in 10-yr cancer 58 
specific survival between active monitoring, radical prostatectomy (RP) or 59 
external beam radiotherapy (EBRT) in men with mainly low- and intermediate-60 
risk PCa, but considerable differences in functional outcomes (3). Since FT has 61 
been mainly performed in smaller low-risk lesions where active surveillance 62 
(AS) is a valid option, the efficacy of FT should be compared to AS and, as such, 63 
long-term follow-up studies are required. In intermediate-risk lesions, a 64 
comparable oncological outcome with a lower side-effect profile would be the 65 
main advantages of FT in comparison with whole gland treatment, in a situation 66 
where an active treatment is needed. 67 
To date, most FTs have been achieved with ablative technologies: 68 
cryotherapy, high-intensity focused ultrasound (HIFU), photodynamic therapy, 69 
electroporation, and focal radiotherapy by brachytherapy or stereotactic EBRT. 70 
All reported modalities of FT are at IDEAL (Idea, Development, Exploration, 71 
Assessment and Long-term follow-up Framework) stage 2b, i.e. they are at an 72 
exploratory phase, with assessment and longer follow-up not yet available (4) 73 
with the exception of PDT where RCT data are available (IDEAL phase 3) (5). 74 
The literature search used for this position paper was similar to that done for the 75 
EAU prostate cancer guidelines (6).  76 
 3 
The concept of FT can only provide long-term benefit to patients if it satisfies 77 
the following requirements:  78 
a) survival efficacy at least equivalent compared to standard of care (SOC);  79 
b) fewer complications and less functional side effects compared to  SOC  80 
c) reliable follow-up of remaining prostatic tissue and  81 
d) potential secondary or salvage treatment not impaired by the primary FT.  82 
 83 
Although FT has also been used for salvage treatments of PCa following local 84 
recurrences after whole gland treatment, this paper will focus on primary 85 
treatment only.  86 
 87 
II. Patient selection 88 
Detailed local staging is essential for selecting patients suitable for focal gland 89 
treatment.  Several consensus meetings have strived to define criteria for patient 90 
selection (Table 1) (7-17). In the most recent publications these have been men 91 
with low-risk (GS 3+3) tumours and a life-expectancy of at least 10 yr. Nowadays 92 
AS is considered to be a valid option in those patients, as well as whole gland 93 
treatments. Any form of FT in low-risk PCa should be associated with significant 94 
clinical benefit compared to these SOC. Patients with a small Gleason 7 (Gleason 95 
sum score 3+4, ISUP 2) lesion might be better candidates although, so far, this 96 
group is rarely considered in the published trials. Multiparametric magnetic 97 
resonance imaging (mpMRI) has been used to select patients in clinical trials 98 
(18-21) and is the standard imaging tool for FT, allowing targeted biopsies. 99 
However, an international consensus project recognised that adding systematic 100 
biopsies remain essential to accurately stage disease (16). These imaging and 101 
sampling modalities must be associated with a high negative predictive value of 102 
significant PCa in regions considered as “normal”. Sextant random biopsies are 103 
insufficient to accurately map tumour locations within the prostate. Instead, 104 
standardised, preferably perineal template-guided saturation, biopsies are 105 
suggested to aid patient selection (19, 22-24).  106 
 107 
Table 1: Summary of consensus reports on focal therapy 108 
 109 
 4 
Publication  Consensus 
topic 
Consensus 
setup 
Patient selection Follow-up Conclusion 
Bostwick 
DG, et al.  
2007 
(7) 
Pathobiology 
definition, 
patient 
selection, 
biopsy 
Not 
provided 
LE > 5 y, T1-3, PSA < 15 
ng/mL, no LUTS, 
bladder stones, 
infections excluded, 3D 
mapping biopsies 5 
mm interval 
 FT reasonable 
consideration in 
selected patients 
De la 
Rosette J, 
et al. 2010 
(8) 
Patient 
selection, 
imaging 
Workshop, 
discussion 
group, 
informal 
Template biopsies, LE > 
10 Y, cave in patients 
with LUTS, low-
intermediate risk, < 
T2c, anterior/apical 
lesions may be difficult, 
long term effects not 
known 
Biopsy 6 mo, 12 
mo, future: 
mpMRI or CEUS, 
3 mo PSA first 
year and 6 mo 
thereafter, 
PROMS 
 
Smeenge 
M, et al.  
2012 
(9) 
Role of TRUS Workshop, 
discussion 
group, 
informal 
TRUS value limited, 
CEUS promising, 
systematic biopsy 
schemes needed 
  
Ahmed HU, 
et al.  
2012 
(10) 
FT and AS Workshop, 
discussion 
group, 
informal 
Transperineal mapping 
biopsy 
 Suggested study 
sequence: proof of 
tumour ablation, 
compare FT to 
existing whole 
gland and/or AS 
Langley S et 
al. 2012 
(11) 
Focal LDR Consensus 
meeting 
LE > 10 y, PSA ≤ 15 
ng/mL, mpMRI, 
template biopsies, 
unilateral < 0.5 cc, 
contralateral < 3 mm 
insignificant disease(GS 
3 + 3, < 3 mm), index 
lesion ≤ GS 3 + 4, <T2c, 
prostate size < 60 cc 
PSA 3 mo 
intervals y 1and 
6 mo thereafter, 
Phoenix criteria, 
mpMRI, PROMS 
Distinction of 
ultra-FT (part of 
lobe), FT (hemi 
gland), focused 
therapy 
(combining whole 
gland and FT) 
Muller BG, 
et al.  
2014 
(12) 
Role of 
mpMRI 
Delphi 
method, 
panel 
meeting  
 Biopsy 6 mo, 12 
mo 
mpMRI preferred 
imaging, FU 6 mo, 
yearly mpMRI, no 
consensus on 
whether mpMRI 
could replace 
biopsies 
Van den 
Bos W, et 
al. 2014 
(13) 
Trial design Delphi 
method, 
panel 
meeting 
PSA < 15 ng/mL, T1c-
2a, GS 3 + 3 or 3 + 4, LE 
> 10 y 
Biopsy 6 mo, 12 
mo 
 
Muller BG, 
et al.  
2015 
(14) 
Follow up Delphi 
method, 
panel 
meeting 
 Minimal 5 y, 
(fusion) 
template TRUS 
biopsies after 1 
y, mpMRI 
(T2WI, DWI, 
DCE, T1W1) at 6 
mo and 12 mo, 
yearly 
thereafter until 
5 y 
 
Donaldson 
IA, et al.  
2015 
(15) 
Patients, 
interventions 
and outcomes 
Delphi 
method, 
panel 
meeting 
Intermediate risk, MRI-
targeted or template 
biopsies, 5 mm 
treatment margin, GS 
6, < 3 mm can be left 
untreated, <20% 
  
 5 
retreatment 
Scheltema 
MJ, et al.  
2017 
(16) 
mpMRI Delphi 
method, 
panel 
meeting 
mpMRI to plan 
treatment 
biopsy Use 1.5T mpMRI 
only with 
endorectal coil, 
fusion MRI-TRUS 
when suspect 
lesion besides 
systemic biopsies 
Tay KJ, et 
al.  
2017 
(17) 
Patient 
selection  
Delphi 
method, 
panel 
meeting 
mpMRI standard 
imaging tool, low/int 
risk PCa, GS 4 + 3, GS 3 
+ 4, foci < 1.5 cc on 
mpMRI, < 20% of the 
prostate, 3 cc or 25% of 
the prostate for 
hemigland treatment. 
Gleason 6 in one core 
in the non-treated 
region is acceptable. 
  
 110 
AS = active surveillance; CEUS = contrast-enhanced ultrasound; FT = focal therapy; 111 
FU = follow up; LE = life-expectancy; LUTS = lower urinary tract symptoms; mpMRI 112 
= multiparametric magnetic resonance imaging ; PROMs = patient-reported 113 
outcome measures;  TRUS = transrectal ultrasound.  114 
 115 
III. Techniques of focal therapy 116 
Several ablative and radiotherapy approaches to FT have been reported. 117 
Comparative studies are scarce and most studies included low- to intermediate-118 
risk PCa treated with curative intent. Regardless of technique, total ablation of 119 
the tumour within the treated area is crucial. Several treatment templates have 120 
been chosen, including hemi-gland, quadrant and lesion targeting. Attempts have 121 
been made to identify the index lesion, i.e. the largest lesion with the highest 122 
Gleason grade in the prostate, to target for FT. In 20% of cases, however, high-123 
grade tumour cells can be found in non-targeted smaller lesions (25) questioning 124 
the validity of this approach. When selecting foci for treatment (15),  planning 125 
should include a 5-mm margin to account for microscopic spread and targeting 126 
error although other authors have suggested a larger safety margin to be 127 
important (26).  Foci of indolent cancer, which can also be present in the 128 
prostate, might be left untreated when treating the dominant index lesion. Table 129 
2 shows the techniques used for FT of primary PCa.  130 
 131 
Table 2: Focal therapy options for primary prostate cancer management 132 
 133 
Technique Ablation Image 
guidance 
Number of 
studies 
FU range Oncological 
outcome 
Incontinence Urinary 
retention 
ED 
 6 
(patients) 
1 Cryotherapy Freeze-thaw 
cycles 
TRUS, 
mpMRI 
12 (n = 2118) 6 – 58 mo 4 – 25% biopsy 
positive 
< 1 % 5% (6 mo) 0 – 31% 
2 HIFU heat TRUS, 
mpMRI 
5 (n = 171) 6 – 24 mo 0 -21% biopsy 
positive 
< 1 % < 5 % 0 – 25% 
3 IRE electroporation mpMRI 
5 (n = 157) 
6 – 12 mo 3 – 33% biopsy 
positive 
< 1 % < 3 % 5 – 10% 
4 Laser heat mpMRI 6 (n = 85) 3 w – 12 
mo 
4 – 64% biopsy 
positive 
< 1 % < 1 % < 5% 
5 Photodynamic 
therapy 
Vascular targeting  TRUS 3 (n = 313) 6 – 24 mo 26 – 51% biopsy 
positive 
< 5 % 7% < 2 % 
6 Brachytherapy radiation TRUS, 
MRI 
dosimetry 
7 (n = 541) 24 – 60 mo 0 – 17% biopsy 
positive 
< 5% nr nr 
 134 
ED = erectile dysfunction, as defined and reported by the studies; FU = follow up; 135 
HIFU = high intensity focused ultrasound; IRE = irreversible electroporation; 136 
mpMRI = multiparametric magnetic resonance imaging; TRUS = transrectal 137 
ultrasound.  138 
 139 
1. Focal cryosurgery ablation of the prostate (fCSAP) 140 
Cryotherapy uses freezing of tissue under ultrasound (US) guidance in one or 141 
multiple cycles to ablate tissue.  This results in a combination of protein 142 
denaturation, direct rupture of cellular membranes by ice crystal formation, and 143 
vascular stasis with development of microthrombi, and consecutive ischaemic 144 
apoptosis. Biochemical recurrence (BCR) at 60 mo for fCSAP was comparable to 145 
whole gland treatment with better erectile function preservation for fCSAP but 146 
similar incidence of voiding problems and fistulas (27). The short follow-up and 147 
comparison of different definitions of BCR render conclusions on oncological 148 
efficacy problematic. The incontinence rates at 1 yr for fCSAP were very low (< 149 
1%), whilst erectile dysfunction rates (ranging from 0-40%) were close to those 150 
for men after RP. Procedural complication rates were generally low, with the 151 
most common being acute urinary retention (range 1.2-8.0%). When compared 152 
to whole gland cryotherapy, fCSAP resulted in a higher rate of erectile function 153 
preservation while continence and oncological outcomes were similar for both 154 
options (28). Using mpMRI-guidance, fCSAP resulted in no deterioration in 155 
erectile function from baseline, and lower urinary tract symptoms remained 156 
unchanged from baseline (29).  157 
 158 
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2. Focal high intensity focused ultrasound (fHIFU) 159 
The principle of HIFU ablation is to focus a high-intensity US beam on a given 160 
target point. The concentration of the beam energy at that point produces a 161 
dramatic temperature rise (up to 80 ◦C in a few seconds). Tissue destruction is 162 
caused by coagulation necrosis and cavitation effects. Systematic reviews (SRs) 163 
of the literature, comparing outcomes of fHIFU with RP or EBRT, found no 164 
comparative studies reporting on oncological continence or potency at 1 yr or 165 
more (30). In a low-to-intermediate risk population treated by hemi-ablation the 166 
local radical retreatment rate was 11% at 2 yr with a 13% grade-3 adverse event 167 
rate (31). In 5 patients who underwent MR-guided focal ablation before RP, no 168 
residual cancer was found in the treated area, but Gleason 7 bilateral cancer, 169 
overlooked by mpMRI, was present outside the treated area in 2 of 5 patients 170 
(32). Three out of fourteen men in a small series with mpMRI guided fHIFU were 171 
diagnosed with Gleason 7 or higher cancer at 24 mo after treatment (33). Barrett 172 
et al. (34) reported a reduction in IIEF score after fHIFU and a moderate increase 173 
in IPSS, suggesting that fHIFU does carry some morbidity.  174 
 175 
3. Irreversible electroporation (IRE) and radiofrequency ablation (RFA) 176 
IRE applies electric current to ablate tissue with a small transition zone between 177 
treated and non-treated tissue (35). However, the IRE ablation zone cannot be 178 
sufficiently visualised by TRUS guidance and although contrast-enhanced US and 179 
mpMRI show promising results, difficulties in targeting tissue remain unresolved 180 
(36, 37) (38). This is confirmed by recent data which showed a narrow safety 181 
margin as a strong predictor of local treatment failure (39) with an infield 182 
recurrence rate of 16%. In 19 men treated with nanoknife IRE, residual disease 183 
was found in 39% (40). Toxicity after IRE is low for ED (<10%) and urinary 184 
retention (3%) (table 2). 185 
 186 
4. Focal laser ablation 187 
MRI-guided laser treatment allows for thermal ablation of specific areas of the 188 
prostate (41-44). In 5 reported series, follow-up was less than 1 yr and residual 189 
disease was present in up to 22% of cases (41). In-bore MRI-guidance may 190 
improve outcome (45). Toxicity for focal laser ablation is reported in under 5% 191 
 8 
of patients.  192 
 193 
5. Photodynamic focal therapy (PFT) 194 
Photosensitisers can be used to ablate tissue by applying light. The formation of 195 
oxygen radicals is believed to underlie the thromboembolic effects of 196 
photodynamic therapy. PFT is the only FT for PCa that was evaluated in a 197 
randomised phase III clinical trial (RCT) comparing hemi-gland ablation (n=207) 198 
and AS (n=206) in men with low-risk disease. This level 1b evidence showed a 199 
reduced rate of positive prostate biopsies at 2 yr in the PFT arm as primary 200 
endpoint (5, 46). In September 2017, the European Medicines Agency granted 201 
marketing authorisation of PFT by padeliporfin for low-risk unilateral PCa. 202 
Although valid at the time of initiation, the study was criticised for including men 203 
with low-risk disease whom, according to current standard practice, would all be 204 
offered AS; therefore, the clinical relevance of this finding is, at the very least, 205 
questionable.  Longer follow-up studies are needed to evaluate overall survival 206 
(OS) data. The most common toxicity for PFT was urinary retention in 7% of 207 
cases early after treatment. 208 
 209 
6. Focal brachytherapy 210 
In a SR, Peach et al. (47) described data from 6 clinical studies and 9 dosimetry 211 
studies on focal high- and low-dose rate brachytherapy. Follow-up in all studies 212 
was less than 60 mo and the recurrence rate was found to be up to 29% in one 213 
series. Toxicity was less, or similar, to whole gland brachytherapy, but this was 214 
found to be dependent on the location of the treated lesion (48). Targeting the 215 
peripheral zone only by iodine-125 sources was found to be associated with high 216 
recurrence rates in intermediate-risk patients (49). In comparison to whole 217 
gland brachytherapy, focal brachytherapy resulted in a markedly lower PSA 218 
reduction in a small group of men (50). Toxicity was reported as less, or similar, 219 
to whole gland treatment, but detailed data are lacking. 220 
 221 
IV. Statements 222 
1. Can focal therapy treat the tumour cell clones most likely to 223 
metastasise? 224 
 9 
The concept of FT is valid when the potentially metastasising tumour clones can 225 
be identified and therefore targeted. The frequent multi-focality of PCa argues 226 
for accurate imaging and histology which is generally obtained by mpMRI and 227 
mapping template biopsies. Potentially metastasising clones may appear early in 228 
the course of the disease (51, 52). Although mpMRI is promising for identifying 229 
larger lesions, it lacks sufficient sensitivity for the detection of smaller lesions 230 
and additional template biopsies are recommended for more accurate staging 231 
and better patient selection (53). In-field recurrences after most focal ablative 232 
treatments do occur and the toxicity of secondary treatments for recurrent 233 
disease is less well known; therefore, further data are essential.  234 
 235 
 Focal therapy can ablate cancer cells but currently, imaging methods 236 
cannot reliably identify all high-risk cancer clones within the prostate 237 
 238 
2. What is the evidence regarding the clinical effectiveness of focal 239 
therapy for localised prostate cancer? 240 
Two recent SRs summarised the data regarding clinical effectiveness of FT. 241 
Ramsay et al. (54) undertook a SR and network meta-analysis of ablative therapy 242 
in men with localised PCa, which included a sub-group analysis of FT vs. RP and 243 
EBRT. Nine case series reporting on FT were identified (5 studies reporting on 244 
focal CSAP, 3 studies on focal HIFU, and 1 study reporting on both). For FT vs. RP 245 
or EBRT, no statistically significant differences were found for BCR at 3 yr. For 246 
focal HIFU vs. RP or EBRT, again, there were no data to compare oncological 247 
outcomes at 1 yr or more, making it impossible to assess oncological 248 
effectiveness of FT.  The high risk of bias and the overall poor data quality of 249 
published papers preclude any reliable conclusions (54). 250 
Similarly, Valerio et al. (30), in a SR including data from 3,230 patients across 251 
37 studies, covering 7 different energy sources for FT, found that the toxicity of 252 
FT is low but, due to lack of a comparator group in most studies, evaluation 253 
against SOC remains to be done.  254 
It should be recognised that most studies on FT include men with low-risk 255 
disease for whom AS is the preferred option. The short-term results from the 256 
only RCT comparing FT and AS are promising. The co-primary endpoints were 257 
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treatment failure at 2 yr (histological progression based on an increased number 258 
of positive cores, an increase in the length of cancer, an increased Gleason score, 259 
an increased PSA > 10 ng/mL or an increased T stage) and absence of definite 260 
cancer. A significant reduced treatment failure was observed with FT even if 261 
evidence of clinical benefit is still missing and clearly deserves longer follow-up 262 
(5). Remarkable variations in follow-up intervals and positive biopsy rates is 263 
apparent among studies (‘Table 1), possibly reflecting the experimental setup of 264 
most studies.  265 
 266 
The literature suggests that the oncological effectiveness of focal 267 
therapy remains unproven due to the lack of reliable comparative data 268 
against SOC including AS. We recommend awaiting prospective 269 
comparative trial data before implementing FT in routine clinical practice. 270 
 271 
3. How does focal therapy compare with whole gland treatment in terms 272 
of complications? 273 
Toxicity of whole gland treatment of localised PCa is caused by damage to 274 
surrounding anatomical structures and depends on the treatment modality (55). 275 
Although less frequent, reports on non-whole gland ablative treatment show 276 
similar types of toxicity compared to whole gland treatment (1, 34) but with 277 
earlier recovery (56). Phase III data suggests that toxicity of photodynamic hemi-278 
ablation exceeds side effects of AS in the initial 2 yr after treatment (46).  279 
 280 
Focal therapy studies targeting smaller regions of the prostate have 281 
reported reduced toxicity compared to whole-gland treatment options but 282 
robust comparative studies with toxicity end-points are still lacking.  283 
 284 
4. Is reliable follow-up of remaining prostatic tissue after focal therapy 285 
for cancer progression possible ? 286 
Close follow-up is essential after FT, since residual disease in the prostate may 287 
lead to disease recurrence and or progression. Neither PSA nor imaging has been 288 
standardised to define recurrence / progression after FT (30). A consensus panel 289 
(15) recommended that histologic outcomes are assessed by targeted biopsy at 1 290 
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yr after treatment (16). Residual disease in the treated area of  <3mm in size and 291 
of Gleason 3 + 3 score were not considered to be in need of further treatment 292 
and focal retreatment rates of less than 20% were considered clinically 293 
acceptable. The need for subsequent whole-gland treatment should be 294 
categorised as failure.  Muller et al. (14) presented results from a consensus 295 
meeting on follow up after FT. Consensus was achieved for at least 5 yr of follow 296 
up using mpMRI, biopsies and functional outcomes assessment. A major 297 
limitation of focal therapy studies is the lack of a uniform definition of disease 298 
recurrence. For comparison with other local therapies comparative studies are 299 
needed. 300 
 301 
Given the considerable uncertainties regarding the optimal follow-up of 302 
men treated with focal therapy, patients should only be treated within the 303 
context of a clinical trial using predefined criteria (6). 304 
 305 
5. Is there an increased toxicity for salvage treatment following failed FT 306 
/recurrence after FT compared to the initial whole gland treatment? 307 
Local recurrence after FT has been reported in 3.6-40% of cases (1, 20, 34). 308 
Several studies reported data on the toxicity of secondary treatment after FT 309 
(57-59). Local salvage therapy after primary whole gland treatment is usually 310 
associated with increased morbidity compared to primary whole gland 311 
treatment (60-63). Complications seem similar for salvage RP after whole gland 312 
and FT but appear to be related to the type of primary FT (57, 64). Data on 313 
retreatment with FT in men with recurrence are scarce. 314 
 315 
Better understanding of the toxicity of secondary and retreatments after 316 
focal therapy is needed and assessment of it should be part of prospective 317 
investigations. 318 
 319 
Conclusions 320 
Focal therapy may reduce the toxicity of whole gland management while 321 
retaining cancer control. However, before widespread clinical introduction clear, 322 
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predefined, clinically relevant objectives are needed, such as a negative biopsy, 323 
OS, disease specific survival and toxicity, as well as optimal follow-up schedules. 324 
Based on the available data, it should be recognised that AS is the preferred 325 
option for many men with low-risk PCa. It is unlikely that FT will provide any 326 
oncological benefits in this population within 10 yr of diagnosis, considering the 327 
low cancer-specific mortality. In intermediate-risk disease, the accurate 328 
detection of higher-risk clones remains problematic and the paucity of relevant  329 
data regarding clinical outcome in such situations is highly problematic. Patients 330 
should be counselled and cautioned that no long-term comparative data on 331 
functional and oncological outcomes are available for FT. The presence of grade 332 
I-III toxicity occurs in up to 28% of cases (31) and the need for retreatment 333 
exists, along with its associated toxicities. Finally, no clear follow-up strategy has 334 
been clarified irrespective of the risk group considered. If long-term benefit is 335 
proven (functional or oncological), FT would represent significant progress in 336 
PCa care. However, thus far, FT must be considered investigational only. 337 
 338 
Patient summary 339 
Focal therapy of prostate cancer is the targeted destruction of cancer within a 340 
specific part of the prostate gland, sparing the rest of the prostate and nearby 341 
tissue. This procedure could potentially reduce side effects when compared to 342 
established standard treatments, such as surgery or radiotherapy, which treat 343 
the entire prostate. Studies show that for most men with low-risk cancer, active 344 
surveillance is the preferred treatment option. However, the available data 345 
regarding all forms of focal therapy is still poor and inconclusive. Consequently, 346 
due to both the lack of clear results associated with focal therapy and the 347 
difficulties in detecting all cancerous areas of the prostate, focal therapy should 348 
considered as investigational only. 349 
 350 
  351 
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